2023
Therapeutic potential of CDK11 in cancer
BLAŽEK, DaliborBasic information
Original name
Therapeutic potential of CDK11 in cancer
Authors
Edition
CLINICAL AND TRANSLATIONAL MEDICINE, ENGLAND, JOHN WILEY & SONS LTD, 2023, 2001-1326
Other information
Language
English
Type of outcome
Article in a journal (not reviewed)
Field of Study
30204 Oncology
Confidentiality degree
is not subject to a state or trade secret
References:
Impact factor
Impact factor: 7.900
RIV identification code
RIV/00216224:14740/23:00139568
Organization unit
Central European Institute of Technology
UT WoS
000940411100001
Keywords in English
cancer; CDK11; OTS964; pladienolide B; spliceosome; splicing
Tags
Tags
International impact
Changed: 4/4/2025 16:14, Mgr. Eva Dubská
Abstract
In the original language
Human cyclin-dependent kinases (CDKs) direct the progression of the cell cycle and transcription. They are deregulated in tumours, and despite their involvement in the regulation of basic cellular processes, many CDKs are promising targets for cancer therapy. CDK11 is an essential gene for the growth of many malignancies; however, its primary cellular function has been obscure, and the mode-of-action of OTS964, the first CDK11 inhibitor and antiproliferative compound, has been unknown. A recent study has shown that OTS964 prevents spliceosome activation, revealing a key role of CDK11 in the regulation of pre-mRNA splicing. In light of these findings, we discuss the therapeutic potential of CDK11 in cancer.
Links
| GA21-19266S, research and development project |
| ||
| GX23-04754X, research and development project |
|